Pleiotropic Effects of Azilsartan Medoxomil Over Insulin Resistance in Obese, Diabetic and Hypertensive Patients
Status:
Unknown status
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to build a mathematical model to explain the effect of two doses of
azilsartan (40 and 80 mg) upon metabolic (insulin resistance, glucose) and inflammatory
parameters (cytokines) in function of "metabolic strata" like obesity, type 2 diabetes
mellitus, hypertension and their combinations.